Tumor Biology

, Volume 36, Issue 5, pp 3703–3708 | Cite as

Downregulation of microRNA-145 is associated with aggressive progression and poor prognosis in human cervical cancer

  • Qingying Wang
  • Jinlong Qin
  • Aozhen Chen
  • Jianhong Zhou
  • Jie Liu
  • Jiajing Cheng
  • Jin Qiu
  • Jiawen Zhang
Research Article


MicroRNAs (miRNAs) play important roles in the processes of tumor initiation and progression. However, miR-145 expression in cervical cancer has been rarely investigated. The aim of this study was to investigate the clinical significance and prognostic value of miR-145 expression in cervical cancer. MiR-145 expression in 114 pairs of human cervical cancer and adjacent normal tissues was detected by real-time quantitative RT-PCR assay. The results showed that miR-145 expression was significantly downregulated in cervical cancer tissues when compared with corresponding adjacent normal tissues (P < 0.001). It was also significantly lower in the cancerous tissues of patients with advanced International Federation of Gynecology and Obstetrics (FIGO) stage cervical cancer than those with early FIGO stage (P = 0.006). In addition, miR-145 was expressed at significantly lower levels in lymph node metastasis-positive patients than in lymph node metastasis-negative patients (P = 0.037). Moreover, poorly differentiated tumors expressed lower miR-145 than well or moderately differentiated tumors (P = 0.012). Patients with vascular invasion or human papillomavirus (HPV) infection also had lower miR-145 expression levels than those without (P = 0.016 and P = 0.025, respectively). Furthermore, Kaplan-Meier analysis showed that cervical cancer patients with low miR-145 expression had shorter overall survival time than those with high miR-145 expression (P < 0.001). When analyzed with a multivariate Cox regression model, miR-145 was identified as an independent prognostic factor for overall survival. Taken together, our results suggest that downregulation of miR-145 in cervical cancer is associated with aggressive progression and poor prognosis and that miR-145 may serve as a prognostic marker.


MicroRNA-145 Cervical cancer Overall survival Prognosis 



We would like to thank Keli Sun (Department of Obstetrics and Gynecology, Shanghai Tenth People’s Hospital) for technical assistance. This study was supported by grants from the Shanghai Science and Technology Committee Foundation (13ZR1432000), and the Foundatio of Shanghai Municipal Health Bureau(YQ 2012-009).

Conflicts of interest



  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Waggoner SE. Cervical cancer. Lancet. 2003;361:2217–25.CrossRefPubMedGoogle Scholar
  3. 3.
    Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.CrossRefPubMedGoogle Scholar
  4. 4.
    Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis. Oncogene. 2006;25:6220–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005;122:6–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell. 2008;13:48–57.CrossRefPubMedGoogle Scholar
  7. 7.
    He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435:828–33.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, Nagel R, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell. 2006;124:1169–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008;14:2348–60.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011;19:232–43.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 2008;3:e2557.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Xing AY, Wang B, Shi DB, Zhang XF, Gao C, He XQ, et al. Deregulated expression of miR-145 in manifold human cancer cells. Exp Mol Pathol. 2013;95:91–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang J, Wang L, Li B, Huo M, Mu M, Liu J, et al. miR-145 downregulates the expression of cyclin-dependent kinase 6 in human cervical carcinoma cells. Exp Ther Med. 2014;8:591–4.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Ambros V. The functions of animal microRNAs. Nature. 2004;431:350–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8:93–103.CrossRefPubMedGoogle Scholar
  17. 17.
    Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120:15–20.CrossRefPubMedGoogle Scholar
  18. 18.
    Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125:345–52.CrossRefPubMedGoogle Scholar
  19. 19.
    Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath CV, Schwartz G, et al. Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res. 2007;67:11612–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, et al. Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers. 2009;26:27–34.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N, Akao Y. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology. 2009;77:12–21.CrossRefPubMedGoogle Scholar
  22. 22.
    Cho WC, Chow AS, Au JS. Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer. 2009;45:2197–206.CrossRefPubMedGoogle Scholar
  23. 23.
    Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene. 2008;27:1788–93.CrossRefPubMedGoogle Scholar
  24. 24.
    Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, et al. Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res. 2009;15:1177–83.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Huang L, Lin JX, Yu YH, Zhang MY, Wang HY, Zheng M. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One. 2012;7:e33762.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Lajer CB, Garnaes E, Friis-Hansen L, Norrild B, Therkildsen MH, Glud M, et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer. 2012;106:1526–34.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, et al. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ. 2010;17:246–54.CrossRefPubMedGoogle Scholar
  29. 29.
    Kodama J, Seki N, Tokumo K, Hongo A, Miyagi Y, Yoshinouchi M, et al. Vascular endothelial growth factor is implicated in early invasion in cervical cancer. Eur J Cancer. 1999;35:485–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Ji R, Cheng Y, Yue J, Yang J, Liu X, Chen H, et al. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ Res. 2007;100:1579–88.CrossRefPubMedGoogle Scholar
  31. 31.
    Cheng Y, Liu X, Yang J, Lin Y, Xu DZ, Lu Q, et al. MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation. Circ Res. 2009;105:158–66.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Cordes KR, Sheehy NT, White MP, Berry EC, Morton SU, Muth AN, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature. 2009;460:705–10.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Zhang C. MicroRNA-145 in vascular smooth muscle cell biology: a new therapeutic target for vascular disease. Cell Cycle. 2009;8:3469–73.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Qingying Wang
    • 1
  • Jinlong Qin
    • 1
  • Aozhen Chen
    • 1
  • Jianhong Zhou
    • 1
  • Jie Liu
    • 1
  • Jiajing Cheng
    • 1
  • Jin Qiu
    • 1
  • Jiawen Zhang
    • 1
  1. 1.Department of Obstetrics and Gynecology, Shanghai Tenth People’s HospitalTongji University School of MedicineShanghaiChina

Personalised recommendations